{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:41:34Z","timestamp":1793353294816,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10067-025-07863-5","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:27:54Z","timestamp":1764433674000},"page":"1947-1957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Short-term efficacy and safety of sublingual cyclobenzaprine for fibromyalgia: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7733-7774","authenticated-orcid":false,"given":"Abd-alrahman","family":"Al-Qudah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5683-1630","authenticated-orcid":false,"given":"Mohammad","family":"Al-Hanaktah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"7863_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2014.3266","volume":"311","author":"DJ Clauw","year":"2014","unstructured":"Clauw DJ (2014) Fibromyalgia: a clinical review. JAMA 311:1547\u20131555. https:\/\/doi.org\/10.1001\/jama.2014.3266","journal-title":"JAMA"},{"key":"7863_CR2","unstructured":"U.S. Food and Drug Administration (2025) NDA 219428 approval letter: Tonmya (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults. U.S. Food and Drug Administration"},{"key":"7863_CR3","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/acr.25142","volume":"75","author":"S Lederman","year":"2023","unstructured":"Lederman S, Arnold LM, Vaughn B, Kelley M, Sullivan GM (2023) Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, double-blind, placebo-controlled trial. Arthritis Care Res 75:2359\u20132368. https:\/\/doi.org\/10.1002\/acr.25142","journal-title":"Arthritis Care Res"},{"key":"7863_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnaf089","author":"S Lederman","year":"2025","unstructured":"Lederman S, Arnold LM, Vaughn B, Engels JM, Kelley M, Sullivan GM (2025) Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. Pain Med. https:\/\/doi.org\/10.1093\/pm\/pnaf089","journal-title":"Pain Med"},{"key":"7863_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2015-eular.2099","volume":"74","author":"RM Gendreau","year":"2015","unstructured":"Gendreau RM, Clauw D, Gendreau J (2015) TNX-102 SL for treatment of fibromyalgia (BESTFIT): randomized, double-blind, placebo-controlled phase 2b trial. Ann Rheum Dis 74:312\u2013312","journal-title":"Ann Rheum Dis"},{"key":"7863_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamainternmed.2020.5651","volume":"181","author":"RO Mascarenhas","year":"2021","unstructured":"Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendon\u00e7a VA, Henschke N, Oliveira VC (2021) Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis. JAMA Intern Med 181:104\u2013112. https:\/\/doi.org\/10.1001\/jamainternmed.2020.5651","journal-title":"JAMA Intern Med"},{"key":"7863_CR7","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"7863_CR8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7863_CR9","unstructured":"Sullivan G, Gendreau R, Gendreau J, Peters A, Peters P, Lederman S (2025) A phase 3 randomized, double-blind, placebo-controlled trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) for the treatment of fibromyalgia (FM): Evidence for a broad spectrum of activity on the FM syndrome. Arthritis Rheumatol [Internet] 71."},{"key":"7863_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.20076","volume":"51","author":"E Tofferi","year":"2004","unstructured":"Tofferi E, Jackson JL, O\u2019Malley PG (2004) Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 51:9\u201313. https:\/\/doi.org\/10.1002\/art.20076","journal-title":"Arthritis Rheum"},{"key":"7863_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, H\u00e4user W et al (2017) EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 76:318\u2013328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209724","journal-title":"Ann Rheum Dis"},{"key":"7863_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","volume":"11","author":"W H\u00e4user","year":"2010","unstructured":"H\u00e4user W, Bernardy K, \u00dc\u00e7eyler N, Sommer C (2010) Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 11:505\u2013521. https:\/\/doi.org\/10.1016\/j.jpain.2010.01.002","journal-title":"J Pain"},{"key":"7863_CR13","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1345\/aph.1D112","volume":"37","author":"K Sayar","year":"2003","unstructured":"Sayar K, Aksu G, Ak I, Tosun M (2003) Venlafaxine treatment of fibromyalgia. Ann Pharmacother 37:1561\u20131565. https:\/\/doi.org\/10.1345\/aph.1D112","journal-title":"Ann Pharmacother"},{"key":"7863_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.080734","volume":"36","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH (2009) The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 36:398\u2013409. https:\/\/doi.org\/10.3899\/jrheum.080734","journal-title":"J Rheumatol"},{"key":"7863_CR15","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1002\/art.20485","volume":"50","author":"LM Arnold","year":"2004","unstructured":"Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ (2004) A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50:2974\u20132984. https:\/\/doi.org\/10.1002\/art.20485","journal-title":"Arthritis Rheum"},{"key":"7863_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","volume":"119","author":"LM Arnold","year":"2005","unstructured":"Arnold LM, Rosen A, Pritchett YL, D\u2019Souza DN, Goldstein DJ, Iyengar S et al (2005) A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5\u201315. https:\/\/doi.org\/10.1016\/j.pain.2005.06.031","journal-title":"Pain"},{"key":"7863_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","volume":"136","author":"IJ Russell","year":"2008","unstructured":"Russell IJ, Mease PJ, Smith TR et al (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136:432\u2013444. https:\/\/doi.org\/10.1016\/j.pain.2008.02.024","journal-title":"Pain"},{"issue":"Suppl 1","key":"7863_CR18","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/hup.622","volume":"19","author":"O Vitton","year":"2004","unstructured":"Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG (2004) A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19(Suppl 1):S27-35. https:\/\/doi.org\/10.1002\/hup.622","journal-title":"Hum Psychopharmacol"},{"key":"7863_CR19","first-page":"1975","volume":"32","author":"RM Gendreau","year":"2005","unstructured":"Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ (2005) Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32:1975\u20131985","journal-title":"J Rheumatol"},{"key":"7863_CR20","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","volume":"30","author":"DJ Clauw","year":"2008","unstructured":"Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y (2008) Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 30:1988\u20132004. https:\/\/doi.org\/10.1016\/j.clinthera.2008.11.009","journal-title":"Clin Ther"},{"key":"7863_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3899\/jrheum.090884","volume":"37","author":"JC Branco","year":"2010","unstructured":"Branco JC, Zachrisson O, Perrot S, Mainguy Y (2010) A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 37:851\u2013859. https:\/\/doi.org\/10.3899\/jrheum.090884","journal-title":"J Rheumatol"},{"issue":"9","key":"7863_CR22","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/art.27559","volume":"62","author":"LM Arnold","year":"2010","unstructured":"Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y (2010) Efficacy and safety of milnacipran 100 mg\/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(9):2745\u20132756. https:\/\/doi.org\/10.1002\/art.27559","journal-title":"Arthritis Rheum"},{"key":"7863_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/14397595.2016.1245237","volume":"27","author":"M Murakami","year":"2017","unstructured":"Murakami M, Osada K, Ichibayashi H, Mizuno H, Ochiai T, Ishida M, Alev L, Nishioka K (2017) An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia. Mod Rheumatol 27:688\u2013695. https:\/\/doi.org\/10.1080\/14397595.2016.1245237","journal-title":"Mod Rheumatol"},{"key":"7863_CR24","doi-asserted-by":"publisher","unstructured":"H\u00e4user W, Urr\u00fatia G, Tort S, U\u00e7eyler N, Walitt B (2013) Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev CD010292. https:\/\/doi.org\/10.1002\/14651858.CD010292","DOI":"10.1002\/14651858.CD010292"},{"key":"7863_CR25","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/AJP.0b013e31828440ab","volume":"29","author":"LM Arnold","year":"2013","unstructured":"Arnold LM, Palmer RH, Ma Y (2013) A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain 29:1021\u20131028. https:\/\/doi.org\/10.1097\/AJP.0b013e31828440ab","journal-title":"Clin J Pain"},{"key":"7863_CR26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3899\/jrheum.101025","volume":"38","author":"JC Branco","year":"2011","unstructured":"Branco JC, Cherin P, Montagne A, Bouroubi A, Multinational Coordinator Study Group (2011) Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol 38:1403\u20131412. https:\/\/doi.org\/10.3899\/jrheum.101025","journal-title":"J Rheumatol"},{"key":"7863_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1526-4637.2009.00755.x","volume":"11","author":"DL Goldenberg","year":"2010","unstructured":"Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM (2010) Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 11:180\u2013194. https:\/\/doi.org\/10.1111\/j.1526-4637.2009.00755.x","journal-title":"Pain Med"},{"key":"7863_CR28","unstructured":"TonmyaTM (cyclobenzaprine HCI) sublingual tablets 2.8mg [Internet]. TonmyaTM HCPs. [cited 2025 Nov 25]. Available from: https:\/\/www.tonmyahcp.com\/"},{"key":"7863_CR29","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/pds.5619","volume":"32","author":"SC Fisher","year":"2023","unstructured":"Fisher SC, Howley MM, Tran EL, Ailes EC, Papadopoulos EA, Nembhard WN, Browne ML, National Birth Defects Prevention Study, Birth Defects Study to Evaluate Pregnancy Exposures (2023) Maternal cyclobenzaprine exposure and risk of birth defects in the National Birth Defects Prevention Study (1997\u20132011) and Birth Defects Study to Evaluate Pregnancy exposureS (2014\u20132018). Pharmacoepidemiol Drug Saf 32:855\u2013862. https:\/\/doi.org\/10.1002\/pds.5619","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7863_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/0890334419843307","volume":"35","author":"B Burra","year":"2019","unstructured":"Burra B, Datta P, Rewers-Felkins K, Baker T, Hale TW (2019) Transfer of cyclobenzaprine into human milk and subsequent infant exposure. J Hum Lact 35:559\u2013562. https:\/\/doi.org\/10.1177\/0890334419843307","journal-title":"J Hum Lact"},{"key":"7863_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00737-018-0933-z","volume":"22","author":"S Gentile","year":"2019","unstructured":"Gentile S, Fusco ML (2019) Managing fibromyalgia syndrome in pregnancy no bridges between USA and EU. Arch Womens Ment Health 22:711\u2013721. https:\/\/doi.org\/10.1007\/s00737-018-0933-z","journal-title":"Arch Womens Ment Health"},{"key":"7863_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12939","volume":"5","author":"HM Farag","year":"2022","unstructured":"Farag HM, Yunusa I, Goswami H, Sultan I, Doucette JA, Eguale T (2022) Comparison of amitriptyline and US Food and Drug Administration-approved treatments for fibromyalgia: a systematic review and network meta-analysis. JAMA Netw Open 5:e2212939. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.12939","journal-title":"JAMA Netw Open"},{"key":"7863_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/keq354","volume":"50","author":"W H\u00e4user","year":"2011","unstructured":"H\u00e4user W, Petzke F, \u00dc\u00e7eyler N, Sommer C (2011) Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology 50:532\u2013543. https:\/\/doi.org\/10.1093\/rheumatology\/keq354","journal-title":"Rheumatology"},{"key":"7863_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/jama.2008.944","volume":"301","author":"W H\u00e4user","year":"2009","unstructured":"H\u00e4user W, Bernardy K, \u00dc\u00e7eyler N, Sommer C (2009) Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 301:198\u2013209. https:\/\/doi.org\/10.1001\/jama.2008.944","journal-title":"JAMA"},{"key":"7863_CR35","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1002\/art.41781","volume":"73","author":"E Ichesco","year":"2021","unstructured":"Ichesco E, Peltier SJ, Mawla I, Harper DE, Pauer L, Harte SE, Clauw DJ, Harris RE (2021) Prediction of differential pharmacologic response in chronic pain using functional neuroimaging biomarkers and a support vector machine algorithm: an exploratory study. Arthritis Rheumatol 73:2127\u20132137. https:\/\/doi.org\/10.1002\/art.41781","journal-title":"Arthritis Rheumatol"},{"key":"7863_CR36","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/acr.25142","volume":"75","author":"S Lederman","year":"2023","unstructured":"Lederman S, Arnold LM, Vaughn B, Kelley M, Sullivan GM (2023) Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, <span class=\"SmallCaps\" style=\"font-weight: normal;\">double-blind, placebo-controlled<\/span> trial. Arthritis Care Res 75:2359\u20132368. https:\/\/doi.org\/10.1002\/acr.25142","journal-title":"Arthritis Care Res"},{"key":"7863_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113974","volume":"301","author":"GM Sullivan","year":"2021","unstructured":"Sullivan GM, Gendreau RM, Gendreau J, Peters P, Peters A, Engels J, Daugherty BL, Vaughn B, Weathers FW, Lederman S (2021) Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res 301:113974. https:\/\/doi.org\/10.1016\/j.psychres.2021.113974","journal-title":"Psychiatry Res"},{"key":"7863_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115764","volume":"334","author":"ME Parmenter","year":"2024","unstructured":"Parmenter ME, Lederman S, Weathers FW, Davis LL, Vaughn B, Engels J, Sullivan GM (2024) A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res 334:115764. https:\/\/doi.org\/10.1016\/j.psychres.2024.115764","journal-title":"Psychiatry Res"},{"key":"7863_CR39","doi-asserted-by":"publisher","first-page":"1651181","DOI":"10.3389\/fphar.2025.1651181","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Li Y, Wu S, Long M, Chen X, Wang Y, Zhao J, He B, Chang C, Jiao J (2025) Pharmacologic treatment of fibromyalgia: an update. Front Pharmacol 16:1651181. https:\/\/doi.org\/10.3389\/fphar.2025.1651181","journal-title":"Front Pharmacol"},{"key":"7863_CR40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/01.ccm.0000810364.00993.8d","volume":"50","author":"C Buyukgoz","year":"2022","unstructured":"Buyukgoz C, Gangu S, Gowani F, Kimura D (2022) 1010: Successful treatment of comatose patient due to cyclobenzaprine overdose with plasma exchange. Crit Care Med 50:502\u2013502. https:\/\/doi.org\/10.1097\/01.ccm.0000810364.00993.8d","journal-title":"Crit Care Med"},{"key":"7863_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.770","volume":"158","author":"J Makram","year":"2020","unstructured":"Makram J, Mallah H, Motes A, Elmassry M, Arevalo M, Paz P, Nugent K (2020) Cyclobenzaprine overdose presenting with rhabdomyolysis, distributive shock, and multiorgan failure. Chest 158:A826. https:\/\/doi.org\/10.1016\/j.chest.2020.08.770","journal-title":"Chest"},{"key":"7863_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1520\/JFS2002308","volume":"48","author":"HA Spiller","year":"2003","unstructured":"Spiller HA, Cutino L (2003) Fatal cyclobenzaprine overdose with postmortem values. J Forensic Sci 48:883\u2013884","journal-title":"J Forensic Sci"},{"key":"7863_CR43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ajem.2010.01.010","volume":"29","author":"C-K How","year":"2011","unstructured":"How C-K, Hou S-K, Shih H-C, Yen DH-T, Huang C-I, Lee C-H, Tang G-J (2011) Usefulness of triggering receptor expressed on myeloid cells-1 in differentiating between typical and atypical community-acquired pneumonia. Am J Emerg Med 29:626\u2013631. https:\/\/doi.org\/10.1016\/j.ajem.2010.01.010","journal-title":"Am J Emerg Med"},{"key":"7863_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6673-1-16","volume":"1","author":"SB Chabria","year":"2006","unstructured":"Chabria SB (2006) Rhabdomyolysis: a manifestation of cyclobenzaprine toxicity. J Occup Med Toxicol 1:16. https:\/\/doi.org\/10.1186\/1745-6673-1-16","journal-title":"J Occup Med Toxicol"},{"key":"7863_CR45","unstructured":"Hazlehurst Pharmacy, Pharmacist to pay up to $2.1 million for dispensing thousands of illegitimate prescriptions [Internet]. [cited 2025 Nov 25]. Available from: https:\/\/www.dea.gov\/press-releases\/2020\/03\/24\/hazlehurst-pharmacy-pharmacist-pay-21-million-dispensing-thousands"},{"key":"7863_CR46","unstructured":"Plaintiff vs ELIZABETH DEMBO [Internet]. [cited 2025 Nov 25]. Available from: https:\/\/www.justice.gov\/file\/1125971\/dl"},{"key":"7863_CR47","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3899\/jrheum.110194","volume":"38","author":"H Moldofsky","year":"2011","unstructured":"Moldofsky H, Inhaber NH, Guinta DR, Alvarez-Horine S, Heithoff KB (2011) Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol 38:2653\u20132663. https:\/\/doi.org\/10.3899\/jrheum.110194","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07863-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07863-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07863-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:53:24Z","timestamp":1771581204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07863-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7863"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07863-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"During the preparation of this work the author(s) used ChatGPT in order to improve readability and language. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}